PT-141(10mg)

PT-141, also known as bremelanotide, is a synthetic peptide that activates melanocortin receptors in the brain to enhance sexual desire and arousal.
Overview
PT-141 is a synthetic, cyclic heptapeptide developed from research on Melanotan II, originally a tanning peptide, which unexpectedly caused sexual arousal in study participants. It is FDA-approved under the brand name Vyleesi for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike medications such as Viagra or Cialis, which act on blood flow, PT-141 works directly on the brain, targeting the MC3R and MC4R melanocortin receptors in the hypothalamus to stimulate dopamine release and trigger sexual desire.Mechanism of Action
PT-141 functions as a melanocortin receptor agonist, primarily activating MC4R pathways. This activation enhances sexual motivation and arousal by increasing dopamine in brain regions responsible for desire. It also indirectly promotes blood flow to sexual organs as part of the natural arousal process, coordinating both mental and physical aspects of sexual response.Administration
PT-141 is typically administered subcutaneously as an on-demand injection. PT-141 is not intended for daily use; it is taken as needed before sexual activity.Effects and Considerations
Users may experience warmth, flushing, or mild nausea shortly after administration, which are common and generally transient. PT-141 is effective for both men and women in research contexts, though FDA approval is currently limited to premenopausal women with HSDD. Its effects are brain-mediated, making it distinct from vasodilators or hormone-based treatments.

Summary
PT-141 is a brain-targeted peptide therapy for sexual desire disorders, acting through melanocortin receptor activation to enhance libido and arousal. It is FDA-approved for women with HSDD, administered on-demand, and works differently from traditional erectile dysfunction or hormone therapies, focusing on the central nervous system rather than peripheral blood flow.